A single-center, placebo-controlled, prospective clinical study for dexamethasone in reducing the early recurrence rate of intussusception in children

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900021390

Enrollment

Unknown

Registered

2019-02-18

Start date

2019-04-01

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intussusception

Interventions

Group A :dexamethasone

Group B:No

Eligibility

Sex/Gender

All

Age

0.3 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Children with mild systemic symptoms or acceptable general condition whose onset is within 48 hours or whose onset is more than 48 hours; 2. Aged 3 months to 18 years; 3. The child has been diagnosed with primary intussusception.

Exclusion criteria

Exclusion criteria: 1. More than 48 hours after the onset, the patient's body condition was poor, and severe dehydration, acidosis, high fever, shock and other clinical manifestations occurred; 2. Patients with severe abdominal distension, signs of intestinal perforation on X-ray examination and signs of peritonitis; 3. Children with intussusception of small intestine; 4. Children with severe congenital heart disease, paralytic intestinal obstruction and other intolerance to enema; 5. 5. Children with previous hormone allergies or other conditions who cannot use hormones; 6. Children with other lesions requiring surgery.

Design outcomes

Primary

Measure	Time frame
the early recurrence rate;	—

Secondary

Measure	Time frame
the number of patients requiring surgery;	—

Countries

China

Contacts

Public ContactChunbao Guo

Children's Hospital of Chongqing Medical University

guochunbao@foxmail.com+86 13032386618

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026